Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

  • Read more about HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders.

  • Read more about Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders.

Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.

  • Read more about Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.

Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

  • Read more about Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

  • Read more about Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

Delayed Recognition and Significant Morbidity in Adults with Non-Transfusion-Dependent Thalassemia.

  • Read more about Delayed Recognition and Significant Morbidity in Adults with Non-Transfusion-Dependent Thalassemia.

Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.

  • Read more about Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.

Yes, we can omit TBI for ALL!

  • Read more about Yes, we can omit TBI for ALL!

Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

  • Read more about Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.

  • Read more about In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.

Pagination

  • Page 1
  • Next page ››
Subscribe to Blood advances

Pediatrics Home

MAKE A GIFT

© 2026 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                   Accessibility  Privacy Policy  Terms of Use  A-Z Website List